Buto

Executive Summary

Buto Corp is a preclinical-stage biotechnology company developing novel small molecule therapeutics targeting innate immune inflammation to treat fibrotic diseases and neurodegenerative conditions. Founded in 2020 and based in San Diego, the company's lead programs focus on lung and liver fibrosis, with potential expansion into Alzheimer's disease. By blocking innate immune pathways, Buto aims to address significant unmet needs in fibrosis and neurodegeneration, where current treatments are limited and disease modification is an urgent goal. The company's approach has the potential to alter disease progression rather than merely manage symptoms. At the preclinical stage, Buto has not disclosed funding or valuation, suggesting it is early in its development trajectory. Key upcoming catalysts include the completion of IND-enabling studies, presentation of preclinical efficacy data at major scientific conferences, and potential partnership or financing deals. Success in these milestones would enable Buto to advance toward clinical trials and attract further investment. However, the company faces typical preclinical risks, including biological validation challenges, manufacturing scale-up, and competition from other therapeutics in fibrosis and CNS disorders.

Upcoming Catalysts (preview)

• Q3 2026Completion of IND-Enabling Studies for Lung Fibrosis Program60% success
• Q3 2026Presentation of Preclinical Data at Major Conference (e.g., ATS or AASLD)75% success
• TBDSeries B or Partnering Deal Announcement50% success